The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Anita Ramelius

Biomedical analyst

Default user image.

Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD-02 study design and first results


  • Christiane Winkler
  • Florian Haupt
  • Martin Heigermoser
  • Jose Zapardiel-Gonzalo
  • Jasmin Ohli
  • Theresa Faure
  • Evdokia Kalideri
  • Angela Hommel
  • Petrina Delivani
  • Reinhard Berner
  • Olga Kordonouri
  • Frank Roloff
  • Thekla von dem Berge
  • Karin Lange
  • Mariusz Oltarzewski
  • Ryszard Glab
  • Agnieszka Szypowska
  • Matthew D. Snape
  • Manu Vatish
  • John A. Todd
  • Helena E. Larsson
  • Anita Ramelius
  • Jeanette Kördel
  • Kristina Casteels
  • Jasmin Paulus
  • Anette G. Ziegler
  • Ezio Bonifacio

Summary, in English

Primary prevention of type 1 diabetes (T1D) requires intervention in genetically at-risk infants. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has established a screening program, GPPAD-02, that identifies infants with a genetic high risk of T1D, enrolls these into primary prevention trials, and follows the children for beta-cell autoantibodies and diabetes. Genetic testing is offered either at delivery, together with the regular newborn testing, or at a newborn health care visits before the age of 5 months in regions of Germany (Bavaria, Saxony, Lower Saxony), UK (Oxford), Poland (Warsaw), Belgium (Leuven), and Sweden (Region Skåne). Seven clinical centers will screen around 330 000 infants. Using a genetic score based on 46 T1D susceptibility single-nucleotide polymorphisms (SNPs) or three SNPS and a first-degree family history for T1D, infants with a high (>10%) genetic risk for developing multiple beta-cell autoantibodies by the age of 6 years are identified. Screening from October 2017 to December 2018 was performed in 50 669 infants. The prevalence of high genetic risk for T1D in these infants was 1.1%. Infants with high genetic risk for T1D are followed up and offered to participate in a randomized controlled trial aiming to prevent beta-cell autoimmunity and T1D by tolerance induction with oral insulin. The GPPAD-02 study provides a unique path to primary prevention of beta-cell autoimmunity in the general population. The eventual benefit to the community, if successful, will be a reduction in the number of children developing beta-cell autoimmunity and T1D.


  • Paediatric Endocrinology
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • Celiac Disease and Diabetes Unit

Publishing year







Pediatric Diabetes





Document type

Journal article




  • Pediatrics
  • Endocrinology and Diabetes


  • beta-cell autoantibodies
  • genetic risk for type 1 diabetes
  • type 1 diabetes



Research group

  • Paediatric Endocrinology
  • Celiac Disease and Diabetes Unit


  • ISSN: 1399-543X